AVXL — Q3 2026 Financial Report Analysis

Anavex Life Sciences reported a $7.8 million profit for its fiscal third quarter (April–June 2026), against a $13.2 million loss a year earlier. The profit is an accounting effect: when the board fired CEO Christopher Missling for cause on April 30, 2026, his unvested stock options were forfeited, and the company reversed $17.1 million of stock-based compensation it had already expensed in earlier periods. Without that reversal, the quarter's loss was about $9.3 million, slightly wider than a year ago. The company still has no revenue. The facts that matter for this report are its $118.3 million of cash, a slower burn rate, and a pipeline now restarting on U.S. regulatory terms after Europe rejected its Alzheimer's application.

Fiscal-year note: Anavex's fiscal year ends September 30, so "Q3 fiscal 2026" is the quarter ended June 30, 2026 (calendar April–June 2026). The 10-Q for this quarter was filed on August 28, 2026, the same day as the delayed Q2 10-Q. Both were late because of the board's review of the former CEO.

At a glance

• Net income of $7.8M ($0.08/share) came almost entirely from a $17.1M non-cash reversal of stock-option expense. Excluding that reversal, the business lost about $9.3M, compared with about $8.9M a year ago.
• Cash burn fell to $9.1M in the quarter, from $12.5M a year earlier. Cash burn is the cash actually spent running the company, and the figure here is operating cash outflow. Cash ended June at $118.3M, which management says funds operations to "mid to late fiscal 2028."
• The Alzheimer's drug is back at an earlier regulatory stage. Europe's drug committee (CHMP) found the key Phase 2b/3 trial formally negative. Anavex now has to agree a new Phase 3 design with the U.S. FDA before it can run a definitive trial.

Q3 fiscal 2026 in numbers

*Our calculations from the filing. "Excluding stock-based comp" adds back the $17.1M reversal this year and removes the $4.3M expense last year. Quarterly cash burn is nine-month operating cash flow ($20.7M) minus the first-half figure in the Q2 10-Q ($11.6M); the prior-year figure is calculated the same way ($30.4M minus $18.0M). "n/m" means not meaningful: a percentage change between a loss and a profit, or a cost that turns negative, doesn't describe anything real.

Takeaway: Ignore the profit. Spending excluding stock awards was flat at about $10.3M for the quarter, and $2.2M of that was legal and advisory cost tied to the CEO's firing. The real changes this quarter were a 27% lower cash burn and a cash pile that now has to carry the company through a new FDA-agreed Phase 3 program, which has not started. The company also cannot use its at-the-market share-sale facility once it files its next annual report.

Why the company reported a profit

Companies expense stock options gradually over the period an employee has to stay to earn them. If the employee leaves before the options vest, the cost already booked is reversed. Anavex's filing attributes $15.5 million of reversals mainly to "the termination of our former CEO for Cause." Another $1.9 million came from milestone-based options the company now says "will never vest given the Company's change in strategy." After new grants, the net reversal was $17.1M. Of that, $9.9M went through the research & development (R&D) line and $7.2M through general & administrative (G&A). Both expense lines therefore came out negative.

No cash came in from these reversals. The reported $0.08 per share profit is a one-time accounting effect. Excluding stock-based compensation, the loss was about $0.10 a share in both years (our calculation).

Where the money actually went

The mix of spending changed more than the total:

• Research spending excluding stock awards fell about 30%, from $7.4M to $5.2M (our calculation from the R&D table). The filing names the causes: $1.2M less in personnel costs after staff cuts and fewer European regulatory consultants; $0.9M less because the ANAVEX 3-71 schizophrenia trial ended in May 2025; and $0.8M less on Rett syndrome after the RS-003 trial's biomarker work was completed. These were partly offset by $1.1M more for clinical pharmacology work. That covers a drug-drug interaction (DDI) study that started this quarter, plus drug manufacturing for an absorption, distribution, metabolism and excretion (ADME) study.
• Administrative spending excluding stock awards nearly doubled, from $2.8M to $5.2M (our calculation). The filing points to about $2.2M of extra legal and professional fees "arising out of the review by the Special Committee." It says these costs will rise further "in future quarters."

In this quarter, the company spent as much on administration as on research. Paying for lawyers is not a long-term use of a drug developer's cash.

What the headline numbers hide

• Cash conversion: Reported net income for the nine months was a $3.2M loss, but $20.7M of cash went out the door. The $15.7M nine-month stock-comp reversal explains almost all of the gap. Cash flow is the more reliable measure of spending here.
• The cash increase came from selling shares, not from operations. Cash rose from $102.6M at the end of September 2025 to $118.3M. Operations used $20.7M over the nine months. The company raised $36.4M by selling 6.0 million new shares through its at-the-market program (a facility for selling shares into the open market over time), and those sales took place in the first fiscal quarter. Shares outstanding rose 7% from September, to 92.7 million.
• Fundraising is about to get harder. Because the Q2 and Q3 10-Qs were filed late, Anavex says it will lose eligibility for Form S-3 after it files its next annual report. Form S-3 is the short-form registration statement that allows quick share sales. The company says it "will be unable to make sales" under the at-the-market agreement, which had $103.2M unused, from that point. Eligibility returns only after 12 months of on-time filings. Sales under the agreement have already been suspended since the special committee was formed.
• Internal controls were not effective. Management concluded that disclosure controls and internal control over financial reporting were ineffective as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026. The weakness is described as a "historical failure to set an appropriate tone at the top." Regulatory and clinical information had been concentrated with the former CEO. The amended 10-K/A states that this did not cause any misstatement of the financial figures, and no numbers were restated.
• Open legal exposure. The former CEO has filed an arbitration demand seeking severance, accelerated equity, damages for alleged defamation and legal fees. He has also sued four independent directors. The company says it "cannot reasonably estimate any potential loss" and has recorded nothing. Older litigation is now mostly resolved. The Rett syndrome shareholder class action was dismissed, and the Second Circuit upheld the dismissal on June 26, 2026. Both derivative suits were dismissed in August 2026.

The pipeline after Europe's rejection

• Alzheimer's (blarcamesine / ANAVEX 2-73): In June 2026 the CHMP published its assessment of the withdrawn European application. It concluded that trial ANAVEX2-73-AD-004 "did not meet its co-primary endpoints." The cognitive score (ADAS-Cog13) was only nominally significant, and the daily-function score (ADCS-ADL) was not significant. The CHMP also found that the favourable cognitive analysis used model changes "made after the study was unblinded," so it treated that analysis as post-hoc. Anavex opened a U.S. Alzheimer's IND (the FDA filing that permits human trials) in March 2026. It has submitted its past trial data under that IND and plans to discuss a new Phase 3 (AD-005) design with the FDA. The new design will draw on the EMA scientific advice received in June. No Phase 3 start date has been given.
• Rett syndrome: The FDA has granted Orphan Drug, Rare Pediatric Disease and Fast Track designations. Anavex is starting an adult Phase 3 (RS-005, about 170 patients, placebo-controlled). In September the FDA granted the company's request for a meeting on adding children to the trial.
• Fragile X syndrome: An IND submission was planned for September 2026.
• Everything else has been paused. ANAVEX 3-71, 1-41 and 1066 are on hold pending outside funding or a partner, and the company says it may license or sell them.

Governance and listing

On May 20, 2026, Nasdaq sent Anavex a delinquency notice for the late Q2 report. Nasdaq confirmed on September 2, 2026 that the company had regained compliance. At the contested September 24 annual meeting, shareholders re-elected all six company nominees and rejected all six nominees put forward by shareholder PVG Asset Management. Under the company's equity plans, the result still counted as a technical "change in control": three directors were first elected in connection with a proxy contest. That triggered immediate vesting of all outstanding unvested awards. This vesting is likely to bring stock-comp expense back onto the income statement in fiscal Q4 (July–September), the opposite of this quarter's reversal. That is our inference; the 8-K does not quantify the charge. Terrie Kellmeyer, Ph.D. is interim CEO.

Outlook

Management guides that cash "is expected to fund operations into mid to late fiscal 2028," which means roughly spring to late summer of 2028. At this quarter's $9.1M burn, $118.3M would last about 13 quarters. The shorter guidance therefore implies spending of roughly $13–17M a quarter once the Rett Phase 3 and Alzheimer's pharmacology studies are fully running (our calculation). The company also says it "will require substantial additional capital" to develop ANAVEX 2-73.

Our view: the cash position is adequate for the next 18 months. The constraint is time. Anavex probably needs an FDA-agreed Alzheimer's Phase 3 design and visible Rett enrolment before late 2027 to raise money on reasonable terms. Losing S-3 eligibility makes that raise slower and more expensive. Things to watch in the fiscal-year 10-K (expected around late November 2026):

1. Whether the FDA has agreed an AD-005 Phase 3 design.
2. When the first patient is dosed in RS-005, and whether children are included.
3. Whether the Fragile X IND has been filed.
4. The size of the Q4 stock-comp charge from accelerated vesting.
5. How much more legal cost the dispute with the former CEO adds.